Current Report Filing (8-k)
August 25 2017 - 4:42PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest
event reported): August 23, 2017
NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified
in Charter)
Delaware
|
|
0-24006
|
|
94-3134940
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
455 Mission Bay Boulevard South
San Francisco, California 94158
(Address of Principal Executive Offices
and Zip Code)
Registrant’s telephone number,
including area code: (415) 482-5300
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
o
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 7.01. Regulation FD Disclosure
On August 23, 2017, Nektar Therapeutics
("Nektar") and Eli Lilly and Company received notice of early termination of the waiting period under the Hart-Scott-Rodino
Act in connection with their License Agreement to co-develop Nektar's proprietary product candidate NKTR-358, which is an investigational
compound that is a potential immunological therapeutic targeting the interleukin receptor complex. Expiration of the waiting period
triggers the effectiveness of the License Agreement and the non-refundable up-front payment to Nektar of $150 million. Please refer
to the Form 8-K Current Report filed by Nektar with the Securities and Exchange Commission on July 24, 2017, for a description
of the License Agreement between Nektar and Eli Lilly and Company.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Nektar Therapeutics
|
|
|
|
Date: August 25, 2017
|
By:
|
/s/ Mark A. Wilson
|
|
|
Mark A. Wilson
|
|
|
General Counsel and Secretary
|
|
|
|
|
|
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Sep 2023 to Sep 2024